Antitumor activity of sorafenib in FLT3-driven leukemic cells (Q33268279)

24 July 2017

title

Antitumor activity of sorafenib in FLT3-driven leukemic cells (English)

1 reference

24 July 2017

1 reference

Auclair D

1

1 reference

24 July 2017

Miller D

2

1 reference

24 July 2017

Yatsula V

3

1 reference

24 July 2017

Pickett W

4

1 reference

24 July 2017

Carter C

5

1 reference

24 July 2017

Chang Y

6

1 reference

24 July 2017

Zhang X

7

1 reference

24 July 2017

Wilkie D

8

1 reference

24 July 2017

Burd A

9

1 reference

24 July 2017

Shi H

10

1 reference

24 July 2017

Rocks S

11

1 reference

24 July 2017

Gedrich R

12

1 reference

24 July 2017

Abriola L

13

1 reference

24 July 2017

Vasavada H

14

1 reference

24 July 2017

Lynch M

15

1 reference

24 July 2017

Dumas J

16

1 reference

24 July 2017

Trail PA

17

1 reference

24 July 2017

Wilhelm SM

18

1 reference

24 July 2017

publication date

4 January 2007

1 reference

24 July 2017

1 reference

24 July 2017

volume

21

1 reference

24 July 2017

issue

3

1 reference

24 July 2017

page(s)

439-445

1 reference

24 July 2017

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

A small molecule-kinase interaction map for clinical kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

FLT3 mutations in acute myeloid leukemia cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

FLT3: ITDoes matter in leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

Internal tandem duplications of Flt3 gene (Flt3/ITD) predicts a poor post-remission outcome in adult patients with acute non-promyelocytic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

FLT3 tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

Inhibition of raf kinase in the treatment of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

The MEK inhibitor, PD98059, reduces survival but does not block acute myeloid leukemia blast maturation in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

An investigation of the effects of the MEK inhibitor U0126 on apoptosis in acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404508

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404508

1 reference

Dimensions Publication ID

24 July 2017

1052091031

0 references

1 reference